Shenzhen Airlines Launches Direct Flight From Shenzhen to Barcelona Successfully
28.8.2023 21:04:00 EEST | Business Wire | Press release
The flight ZH9065 with 203 passengers on board, which took off from Shenzhen of China, landed in Barcelona of Spain in the morning on August 28, marked the new direct flight has been launched successfully by Shenzhen Airlines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230828849009/en/
Zhou Zhiwei(L6), board member and executive vice president of Shenzhen Airlines, and Hu Aimin(L5), the deputy consul-general of China in Barcelona, welcome the cabin crew and passengers of the debut flight of Shenzhen-Barcelona route in Barcelona on August 28. (Photo: Business Wire)
Together with the Barcelona municipality, the general consulate of China in Barcelona, the Air Routes Development Committee in Barcelona (CDRA), Network of airports in Spain (AENA), the Shenzhen airlines and its partner Air China, organized a warm ceremony to welcome the passengers, while the major of Barcelona, the deputy consul-general of China in Barcelona, and dozens of representatives of those organizers attended the event.
The round flight connecting Shenzhen and Barcelona is operated by Shenzhen Airlines twice a week, on every Monday and Friday. Flight ZH9066 from Barcelona to Shenzhen departs at 11:30 local time and arrives at 07:00 Beijing time, the return flight ZH9065 departs at 11:30 and arrives at 08:05.
The advanced Airbus A330 wide-body passenger aircraft has been invested in this new route, which brings every people a comfortable journey.
In addition, passengers taking this flight are provided with cross-city transfers, free transit hotels, express visa process, and other exclusive services.
Shenzhen Airlines was established in 1992 in Shenzhen, one of the core cities of the Guangdong-Hong Kong-Macao Greater Bay Area in China. With 226 passenger aircraft of various types, the fleet of Shenzhen Airlines ranks the fifth in China. Supporting by 15 branches or bases across the whole country, Shenzhen Airlines operates now more than 200 routes, covering the major destinations in China and abroad.
Shenzhen is one of the five major airports in China, also an important transportation hub in the Asia-Pacific region, plays an important role for connecting China and the other countries.
2023 marks the 50th anniversary of the establishment of diplomatic relations between Spain and China, and the second anniversary of Barcelona and Shenzhen becoming sister cities. The new route sets up a convenient air bridge between the two cities, which will further promote the cooperation between the two places and even between the two nations in the fields of sci-tech, culture, tourism, and trade.
The new route is Shenzhen Airlines' second direct flight from Europe following the first one between London and Shenzhen. Shenzhen Airlines will continue to enrich the route network in near future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230828849009/en/
Contact information
Z. Pan info@xinhuaeurope.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 11:00:00 EET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 11:00:00 EET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 11:00:00 EET | Press release
The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying the foundations for the evolution of AI-supported oncological diagnostics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210610418/en/ On this
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 11:00:00 EET | Press release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 10:15:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living with NT1. NT1 is a chronic, rare neurological disease caused by a loss of orexin and characterized by excessive daytime sleepiness and cataplexy (sudden loss of muscle tone). This results in a spectrum of physical, cognitive and psychosocial effects that can have a debilitating impact on many aspects of a person’s life, including work, education and social interactio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom